The revolution of personalized pharmacotherapies for cystic fibrosis: what does the future hold?

References

• Guo J, Garratt A, Hill A. Worldwide rates of diagnosis and effective treatment for cystic fibrosis. J Cyst Fibros. 2022;21(3):456–462. doi: 10.1016/j.jcf.2022.01.009.
   PubMed Web of Science ®Google Scholar
• Lopes-Pacheco M. CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine. Front Pharmacol. 2020;10:1662. doi: 10.3389/fphar.2019.01662
   PubMed Web of Science ®Google Scholar
• Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989;245:1059–1065. DOI:10.1126/science.2772657
   PubMed Web of Science ®Google Scholar
• Riordan JR, Rommens JM, Kerem BS, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245:1066–1073. DOI:10.1126/science.2475911
   PubMed Web of Science ®Google Scholar
• Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245(4922):1073–1080. doi: 10.1126/science.2570460
   PubMed Web of Science ®Google Scholar
• Saint-Criq V, Gray MA. Role of CFTR in epithelial physiology. Cell Mol Life Sci. 2017;74(1):93–115. doi: 10.1007/s00018-016-2391-y
   PubMed Web of Science ®Google Scholar
• Lopes-Pacheco M. CFTR modulators: shedding light on precision medicine for cystic fibrosis. Front Pharmacol. 2016;7:275. doi: 10.3389/fphar.2016.00275
   PubMed Web of Science ®Google Scholar
• Liu F, Zhang Z, Csanády L, et al. Molecular structure of the human CFTR ion channel. Cell. 2017;169(1):85–95.e8. doi: 10.1016/j.cell.2017.02.024
   PubMed Web of Science ®Google Scholar
• Csanády L, Vergani P, Gadsby DC. Structure, gating, and regulation of the CFTR anion channel. Physiol Rev. 2019;99(1):707–738. doi: 10.1152/physrev.00007.2018
   PubMed Web of Science ®Google Scholar
• Kim SJ, Skach WR. Mechanisms of CFTR folding at the endoplasmic reticulum. Front Pharmacol. 2012;3:201. doi: 10.3389/fphar.2012.00201
   PubMed Web of Science ®Google Scholar
• Zhang Z, Liu F, Chen J. Molecular structure of the ATP-bound, phosphorylated human CFTR. Proc Natl Acad Sci U S A. 2018;115(50):12757–12762. doi: 10.1073/pnas.1815287115
   PubMed Web of Science ®Google Scholar
• Cystic Fibrosis Mutation Database (CFTR1 Database) [Internet]. Available from: http://www.genet.sickkids.on.ca/.
   Google Scholar
• Clinical and Function Translation of CFTR (CFTR2 Database) [Internet]. Available from: https://cftr2.org/.
   Google Scholar
• Marson FAL, Bertuzzo CS, Ribeiro JD. Classification of CFTR mutation classes. Lancet Respir Med. 2016;4(8):e37–e38. doi: 10.1016/S2213-2600(16)30188-6
   PubMedGoogle Scholar
• Ensinck MM, Carlon MS. One size does not fit all: the past, present and future of cystic fibrosis causal therapies. Cells. 2022;11(12):1868. doi: 10.3390/cells11121868
   PubMed Web of Science ®Google Scholar
• Southern KW, Castellani C, Lammertyn E, et al. Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis. J Cyst Fibros. 2023;22(1):17–30. doi: 10.1016/j.jcf.2022.10.002
   PubMed Web of Science ®Google Scholar
• Narayanan S, Mainz JG, Gala S, et al. Adherence to therapies in cystic fibrosis: a targeted literature review. Expert Rev Respir Med. 2017;11(2):129–145. InternetAvailable from. doi: http://dx.doi.org/10.1080/17476348.2017.1280399
   PubMed Web of Science ®Google Scholar
• Ramsey BW, Davies JC, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663–1672. doi: 10.1056/NEJMoa1105185
   PubMed Web of Science ®Google Scholar
• Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373(3):220–231. doi: 10.1056/NEJMoa1409547
   PubMed Web of Science ®Google Scholar
• Taylor-Cousar JL, Munck A, McKone EF, et al. Tezacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del. N Engl J Med. 2017;377(21):2013–2023. doi: 10.1056/NEJMoa1709846
   PubMed Web of Science ®Google Scholar
• Rowe SM, Daines C, Ringshausen FC, et al. Tezacaftor–ivacaftor in residual-function heterozygotes with cystic fibrosis. N Engl J Med. 2017;377(21):2024–2035. doi: 10.1056/NEJMoa1709847
   PubMed Web of Science ®Google Scholar
• Heijerman HGM, McKone EF, Downey DG, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394(10212):1940–1948. doi: 10.1016/S0140-6736(19)32597-8
   PubMed Web of Science ®Google Scholar
• Middleton PG, Mall MA, Dřevínek P, et al. Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single Phe508del Allele. N Engl J Med. 2019;381:p. 1809–1819.
   Google Scholar
• Bacalhau M, Camargo M, Magalhães-Ghiotto GAV, et al. Elexacaftor-tezacaftor-ivacaftor: a life-changing triple combination of CFTR modulator drugs for cystic fibrosis. Pharmaceuticals. 2023;16(3):410. doi: 10.3390/ph16030410
   Web of Science ®Google Scholar
• Lopes-Pacheco M, Pedemonte N, Veit G. Discovery of CFTR modulators for the treatment of cystic fibrosis. Expert Opin Drug Discov. 2021;16(8):897–913. doi: 10.1080/17460441.2021.1912732
   PubMed Web of Science ®Google Scholar
• Silva IAL, Laselva O, Lopes-Pacheco M. Advances in preclinical in vitro models for the translation of precision medicine for cystic fibrosis. J Pers Med. 2022;12(8):1321. doi: 10.3390/jpm12081321
   PubMed Web of Science ®Google Scholar
• Okiyoneda T, Veit G, Dekkers JF, et al. Mechanism-based corrector combination restores ΔF508-CFTR folding and function. Nat Chem Biol. 2013;9(7):444–454. doi: 10.1038/nchembio.1253
   PubMed Web of Science ®Google Scholar
• Van Goor F, Hadida S, Grootenhuis PDJ, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A. 2011;108(46):18843–18848. doi: 10.1073/pnas.1105787108
   PubMed Web of Science ®Google Scholar
• Veit G, Avramescu RG, Perdomo D, et al. Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression. Sci Transl Med. 2014;6(246):246ra97. doi: 10.1126/scitranslmed.3008889
   PubMed Web of Science ®Google Scholar
• Lopes-Pacheco M, Boinot C, Sabirzhanova I, et al. Combination of correctors rescue ΔF508-CFTR by reducing its association with Hsp40 and Hsp27. J Biol Chem. 2015;290(42):25636–25645. doi: 10.1074/jbc.M115.671925
   PubMed Web of Science ®Google Scholar
• Farinha CM, King-Underwood J, Sousa M, et al. Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction. Chem Biol. 2013;20(7):943–955. doi: 10.1016/j.chembiol.2013.06.004
   PubMed Web of Science ®Google Scholar
• Lopes-Pacheco M, Silva IAL, Turner MJ, et al. Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR. Biochem Pharmacol. 2020;180:114133. DOI:10.1016/j.bcp.2020.114133
   PubMed Web of Science ®Google Scholar
• Ren HY, Grove DE, De La Rosa O, et al. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1. Mol Biol Cell. 2013;24(19):3016–3024. doi: 10.1091/mbc.e13-05-0240
   PubMed Web of Science ®Google Scholar
• Loo TW, Bartlett MC, Clarke DM. Corrector VX-809 stabilizes the first transmembrane domain of CFTR. Biochem Pharmacol. 2013;86(5):612–619. doi: 10.1016/j.bcp.2013.06.028
   PubMed Web of Science ®Google Scholar
• Krainer G, Schenkel M, Hartmann A, et al. CFTR transmembrane segments are impaired in their conformational adaptability by a pathogenic loop mutation and dynamically stabilized by Lumacaftor. J Biol Chem. 2020;295(7):1985–1991. doi: 10.1074/jbc.AC119.011360
   PubMed Web of Science ®Google Scholar
• He L, Kota P, Aleksandrov AA, et al. Correctors of ΔF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein. Faseb J. 2013;27(2):536–545. doi: 10.1096/fj.12-216119
   PubMed Web of Science ®Google Scholar
• Fiedorczuk K, Chen J. Mechanism of CFTR correction by type I folding correctors. Cell. 2022;185(1):158–168.e11. doi: 10.1016/j.cell.2021.12.009
   PubMed Web of Science ®Google Scholar
• Veit G, Xu H, Dreano E, et al. Structure-guided combination therapy to potently improve the function of mutant CFTRs. Nat Med. 2018;24(11):1732–1742. Internet. doi: 10.1038/s41591-018-0200-x
   PubMed Web of Science ®Google Scholar
• Veit G, Roldan A, Hancock MA, et al. Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination. JCI Insight. 2020;5(18):e139983. doi: 10.1172/jci.insight.139983
   PubMed Web of Science ®Google Scholar
• Lopes-Pacheco M, Ferreira FC, Bacalhau M. ePS6.01 Characterisation of F508del-CFTR rescue by corrector PTI-801. J Cyst Fibros. 2022;21:S58. doi: 10.1016/S1569-1993(22)00328-9
   Google Scholar
• Bacalhau M, Ferreira FC, Kmit A, et al. Identification of novel F508del-CFTR traffic correctors among triazole derivatives. Eur J Pharmacol. 2023;938:175396. DOI:10.1016/j.ejphar.2022.175396
   PubMed Web of Science ®Google Scholar
• Singh AK, Fan Y, Balut C, et al. Biological characterization of F508DelCFTR protein processing by the CFTR corrector ABBV-2222/GLPG2222. J Pharmacol Exp Ther. 2020;372(1):107–118. doi: 10.1124/jpet.119.261800
   PubMed Web of Science ®Google Scholar
• Bell SC, Barry PJ, De Boeck K, et al. CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials. J Cyst Fibros. 2019;18(5):700–707. doi: 10.1016/j.jcf.2019.04.014
   PubMed Web of Science ®Google Scholar
• Pedemonte N, Bertozzi F, Caci E, et al. Discovery of a picomolar potency pharmacological corrector of the mutant CFTR chloride channel. Sci Adv. 2020;6(8):eaay9669. doi: 10.1126/sciadv.aay9669
   PubMed Web of Science ®Google Scholar
• Pedemonte N, Lukacs GL, Du K, et al. Small-molecule correctors of defective F508-CFTR cellular processing identified by high-throughput screening. J Clin Invest. 2005;115(9):2564–2571. doi: 10.1172/JCI24898
   PubMed Web of Science ®Google Scholar
• Lopes-Pacheco M, Sabirzhanova I, Rapino D, et al. Correctors rescue CFTR mutations in nucleotide-binding domain 1 (NBD1) by modulating proteostasis. Chembiochem. 2016;17(6):493–505. doi: 10.1002/cbic.201500620
   PubMed Web of Science ®Google Scholar
• Lopes-Pacheco M, Boinot C, Sabirzhanova I, et al. Combination of correctors rescues CFTR transmembrane-domain mutants by mitigating their interactions with Proteostasis. Cell Physiol Biochem. 2017;41(6):2194–2210. doi: 10.1159/000475578
   PubMedGoogle Scholar
• Wang Y, Loo TW, Bartlett MC, et al. Correctors promote maturation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)-processing mutants by binding to the protein. J Biol Chem. 2007;282(46):33247–33251. doi: 10.1074/jbc.C700175200
   PubMed Web of Science ®Google Scholar
• Laselva O, Molinski S, Casavola V, et al. Correctors of the major cystic fibrosis mutant interact through membrane-spanning domains. Mol Pharmacol. 2018;93(6):612–618. doi: 10.1124/mol.118.111799
   PubMed Web of Science ®Google Scholar
• Pesce E, Bellotti M, Liessi N, et al. Synthesis and structure-activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis. Eur J Med Chem [InternetAvailable from]. 2015;99:14–35. doi: 10.1016/j.ejmech.2015.05.030
   PubMed Web of Science ®Google Scholar
• Capurro V, Tomati V, Sondo E, et al. Partial rescue of f508del-cftr stability and trafficking defects by double corrector treatment. Int J Mol Sci. 2021;22(10):5262. doi: 10.3390/ijms22105262
   PubMed Web of Science ®Google Scholar
• Baatallah N, Elbahnsi A, Mornon J-P, et al. Pharmacological chaperones improve intra-domain stability and inter-domain assembly via distinct binding sites to rescue misfolded CFTR. Cell Mol Life Sci. 2021;78(23):7813–7829. Internet. doi: 10.1007/s00018-021-03994-5
   PubMed Web of Science ®Google Scholar
• Davies JC, Moskowitz SM, Brown C, et al. VX-659–Tezacaftor–Ivacaftor in patients with cystic fibrosis and one or two Phe508del Alleles. N Engl J Med. 2018;379(17):1599–1611. doi: 10.1056/NEJMoa1807119
   PubMed Web of Science ®Google Scholar
• Fiedorczuk K, Chen J. Molecular structures reveal synergistic rescue of Δ508 CFTR by Trikafta modulators. Science. 2022;378(6617):284–290. doi: 10.1126/science.ade2216.
   PubMedGoogle Scholar
• Im J, Hillenaar T, Yeoh HY, et al. ABC-transporter CFTR folds with high fidelity through a modular, stepwise pathway. Cell Mol Life Sci. 2023;80(1):33. doi: 10.1007/s00018-022-04671-x
   PubMed Web of Science ®Google Scholar
• Uluer AZ, MacGregor G, Azevedo P, et al. Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials. Lancet Respir Med. 2023;11(6):550–562. doi: 10.1016/S2213-2600(22)00504-5
   PubMed Web of Science ®Google Scholar
• Lopes-Pacheco M, Bacalhau M, Ramalho SS, et al. Rescue of mutant CFTR trafficking defect by the investigational compound MCG1516A. Cells. 2022;11(1):136. doi: 10.3390/cells11010136
   PubMed Web of Science ®Google Scholar
• De Wilde G, Gees M, Musch S, et al. Identification of GLPG/ABBV-2737, a novel class of corrector, which exerts functional synergy with other CFTR modulators. Front Pharmacol. 2019;10:514. DOI:10.3389/fphar.2019.00514
   PubMed Web of Science ®Google Scholar
• Scanio MJC, Searle XB, Liu B, et al. Discovery of ABBV/GLPG-3221, a potent corrector of CFTR for the treatment of cystic fibrosis. ACS Med Chem Lett. 2019;10(11):1543–1548. doi: 10.1021/acsmedchemlett.9b00377
   PubMed Web of Science ®Google Scholar
• Greszler SN, Zhao G, Shelat B, et al. Enabling asymmetric synthesis of ABBV-3748, a corrector compound for the treatment of cystic fibrosis. Org Lett. 2022;24(40):7305–7308. doi: 10.1021/acs.orglett.2c02729
   PubMed Web of Science ®Google Scholar
• Hurlbut G, Altmann S, Barrague M, et al. 662 Novel cystic fibrosis transmembrane conductance regulator modulator combinations that address the first nucleotide binding domain defect central to ΔF508 dysfunction enable full correction of cystic fibrosis transmembrane conductance regulator. J Cyst Fibros. 2022;21:S362–S363. DOI:10.1016/S1569-1993(22)01352-2
   Google Scholar
• Van Goor F, Hadida S, Grootenhuis PDJ, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009;106(44):18825–18830. doi: 10.1073/pnas.0904709106
   PubMed Web of Science ®Google Scholar
• Eckford PDW, Li C, Ramjeesingh M, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J Biol Chem. 2012;287(44):36639–36649. doi: 10.1074/jbc.M112.393637
   PubMed Web of Science ®Google Scholar
• Jih KY, Hwang TC. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle. Proc Natl Acad Sci U S A. 2013;110(11):4404–4409. doi: 10.1073/pnas.1215982110
   PubMed Web of Science ®Google Scholar
• Laselva O, Bartlett C, Gunawardena TNA, et al. Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator. Eur Respir J. 2021;57(6):2002774. doi: 10.1183/13993003.02774-2020
   PubMed Web of Science ®Google Scholar
• Veit G, Vaccarin C, Lukacs GL. Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR. J Cyst Fibros. 2021;20(5):895–898. doi: 10.1016/j.jcf.2021.03.011 InternetAvailable from.
   PubMed Web of Science ®Google Scholar
• CFF - Drug Development Pipeline [Internet]. Available from: https://apps.cff.org/trials/pipeline/.
   Google Scholar
• Harbeson SL, Morgan AJ, Liu JF, et al. Altering metabolic profiles of drugs by precision deuteration 2: discovery of a deuterated analog of ivacaftor with differentiated pharmacokinetics for clinical development. J Pharmacol Exp Ther. 2017;362(2):359–367. doi: 10.1124/jpet.117.241497
   PubMed Web of Science ®Google Scholar
• Gees M, Musch S, Van Der Plas S, et al. Identification and characterization of novel CFTR potentiators. Front Pharmacol. 2018;9:1221. DOI:10.3389/fphar.2018.01221
   PubMed Web of Science ®Google Scholar
• Van Der Plas SE, Kelgtermans H, Mammoliti O, et al. Discovery of GLPG2451, a novel once daily potentiator for the treatment of cystic fibrosis. J Med Chem. 2021;64(1):343–353. doi: 10.1021/acs.jmedchem.0c01796
   PubMed Web of Science ®Google Scholar
• Veit G, Da Fonte DF, Avramescu RG, et al. Mutation-specific dual potentiators maximize rescue of CFTR gating mutants. J Cyst Fibros. 2020;19(2):236–244. doi: 10.1016/j.jcf.2019.10.011
   PubMed Web of Science ®Google Scholar
• Yeh H-I, Qiu L, Sohma Y, et al. Identifying the molecular target sites for CFTR potentiators GLPG1837 and VX-770. J Gen Physiol. 2019;151(7):912–928. doi: 10.1085/jgp.201912360
   PubMed Web of Science ®Google Scholar
• Liu F, Zhang Z, Levit A, et al. Structural identification of a hotspot on CFTR for potentiation. Science. 2019;364(6446):1184–1188. doi: 10.1126/science.aaw7611
   PubMed Web of Science ®Google Scholar
• Grand DL, Gosling M, Baettig U, et al. Discovery of icenticaftor (QBW251), a cystic fibrosis transmembrane conductance regulator potentiator with clinical efficacy in cystic fibrosis and chronic obstructive pulmonary disease. J Med Chem. 2021;64(11):7241–7260. doi: 10.1021/acs.jmedchem.1c00343
   PubMed Web of Science ®Google Scholar
• Cholon D, Aleksandrov L, Quinney N, et al. 647 potentiator icenticaftor is superior to ivacaftor in rescuing F508del cystic fibrosis transmembrane conductance regulator and does not destabilize corrected mature protein. J Cyst Fibros. 2022;21:S355. DOI:10.1016/S1569-1993(22)01337-6
   Google Scholar
• Cholon DM, Quinney NL, Fulcher ML, et al. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis. Sci Transl Med. 2014;6(246):246ra96. doi: 10.1126/scitranslmed.3008680
   PubMed Web of Science ®Google Scholar
• Moran O, Zegarra-Moran O. A quantitative description of the activation and inhibition of CFTR by potentiators: genistein. FEBS Lett. 2005;579(18):3979–3983. doi: 10.1016/j.febslet.2005.06.026
   PubMed Web of Science ®Google Scholar
• Phuan PW, Son JH, Tan JA, et al. Combination potentiator (‘co-potentiator’) therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators. J Cyst Fibros [InternetAvailable from]. 2018;17:595–606. doi: 10.1016/j.jcf.2018.05.010
   PubMed Web of Science ®Google Scholar
• Wang F, Zeltwanger S, Yang IC, et al. Actions of genistein on cystic fibrosis transmembrane conductance regulator channel gating. Evidence for two binding sites with opposite effects. J Gen Physiol. 1998;111(3):477–490. doi: 10.1085/jgp.111.3.477
   PubMed Web of Science ®Google Scholar
• Moran O, Galietta LJV, Zegarra-Moran O. Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains. CMLS, Cell Mol Life Sci. 2005;62(4):446–460. doi: 10.1007/s00018-004-4422-3
   PubMed Web of Science ®Google Scholar
• Liu J, Berg AP, Wang Y, et al. A small molecule CFTR potentiator restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR. Br J Pharmacol. 2022;179(7):1319–1337. doi: 10.1111/bph.15709
   PubMed Web of Science ®Google Scholar
• Bacalhau M, Ferreira FC, Silva IAL, et al. Additive potentiation of R334W-CFTR function by novel small molecules. J Pers Med. 2023;13(1):102. doi: 10.3390/jpm13010102
   PubMed Web of Science ®Google Scholar
• Downey DG, Fajac I, Flume P, et al. Ws11.5 Evaluation of combinations of the CFTR potentiator dirocaftor, corrector posenacaftor and amplifier nesolicaftor in cystic fibrosis subjects with two copies of the F508del mutation. J Cyst Fibros. 2020;19:S19. DOI:10.1016/S1569-1993(20)30226-5
   PubMedGoogle Scholar
• Cole B, Bhatt P, Bailey V, et al. 31 Distinguishing properties of CFTR potentiator FDL176. J Cyst Fibros. 2017;16:S71. DOI:10.1016/S1569-1993(17)30396-X
   Google Scholar
• Volkova N, Moy K, Evans J, et al. Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries. J Cyst Fibros. 2020;19(1):68–79. doi: 10.1016/j.jcf.2019.05.015
   PubMed Web of Science ®Google Scholar
• Phuan PW, Tan JA, Rivera AA, et al. Nanomolar-potency ‘co-potentiator’ therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants. Sci Rep. 2019;9(1):1–12. doi: 10.1038/s41598-019-54158-2
   PubMed Web of Science ®Google Scholar
• Haggie PM, Phuan PW, Tan JA, et al. Correctors and potentiators rescue function of the truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) translation product. J Biol Chem. 2017;292(3):771–785. doi: 10.1074/jbc.M116.764720
   PubMed Web of Science ®Google Scholar
• Ensinck MM, De Keersmaecker L, Ramalho AS, et al. Novel CFTR modulator combinations maximise rescue of G85E and N1303K in rectal organoids. ERJ Open Res. 2022;8(2):00716–02021. doi: 10.1183/23120541.00716-2021
   PubMedGoogle Scholar
• Hellen CUT. Translation termination and ribosome recycling in eukaryotes. Cold Spring Harb Perspect Biol. 2018;10(10):a032656. doi: 10.1101/cshperspect.a032656
   PubMed Web of Science ®Google Scholar
• Joazeiro CAP. Mechanisms and functions of ribosome-associated protein quality control. Nat Rev Mol Cell Biol. 2019;20(6):368–383. doi: 10.1038/s41580-019-0118-2
   PubMed Web of Science ®Google Scholar
• Yi Z, Sanjeev M, Singh G. The branched nature of the nonsense-mediated mRNA decay pathway. Trends Genet. 2021;37(2):143–159. doi: 10.1016/j.tig.2020.08.010
   PubMed Web of Science ®Google Scholar
• Powers KT, Szeto J-Y, Schaffitzel C. New insights into no-go, non-stop and nonsense-mediated mRNA decay complexes. Curr Opin Struct Biol. 2020;65:110–118. doi: 10.1016/j.sbi.2020.06.011
   PubMed Web of Science ®Google Scholar
• Oren YS, Pranke IM, Kerem B, et al. The suppression of premature termination codons and the repair of splicing mutations in CFTR. Curr Opin Pharmacol. 2017;34:125–131. DOI:10.1016/j.coph.2017.09.017
   PubMed Web of Science ®Google Scholar
• Sharma N, Evans TA, Pellicore MJ, et al. Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis. PLoS Genet. 2018;14(11):e1007723. doi: 10.1371/journal.pgen.1007723
   PubMed Web of Science ®Google Scholar
• Spelier S, van Doorn EPM, van der Ent CK, et al. Readthrough compounds for nonsense mutations: bridging the translational gap. Trends Mol Med. 2023;29(4):297–314. doi: 10.1016/j.molmed.2023.01.004
   PubMed Web of Science ®Google Scholar
• Shao S, Murray J, Brown A, et al. Decoding Mammalian Ribosome-Mrna states by translational GTPase complexes. Cell. 2016;167(5):1229–1240.e15. doi: 10.1016/j.cell.2016.10.046
   PubMed Web of Science ®Google Scholar
• Pettersen EF, Goddard TD, Huand CC, et al. UCSF Chimera?A visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605–1612. doi: 10.1002/jcc.20084
   PubMed Web of Science ®Google Scholar
• Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet. 2008;372(9640):719–727. doi: 10.1016/S0140-6736(08)61168-X
   PubMed Web of Science ®Google Scholar
• Kerem E, Konstan MW, De Boeck K, et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med [InternetAvailable from]. 2014;2:539–547. doi: 10.1016/S2213-2600(14)70100-6
   PubMed Web of Science ®Google Scholar
• Wilhelm JM, Jessop JJ, Pettitt SE. Aminoglycoside antibiotics and eukaryotic protein synthesis: stimulation of errors in the translation of natural messengers in extracts of cultured human cells. Biochemistry. 1978;17(7):1149–1153. doi: 10.1021/bi00600a002
   PubMed Web of Science ®Google Scholar
• Konstan MW, VanDevanter DR, Rowe SM, et al. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). J Cyst Fibros [InternetAvailable from]. 2020;19:595–601. doi: 10.1016/j.jcf.2020.01.007
   PubMed Web of Science ®Google Scholar
• Peabody Lever JE, Mutyam V, Hathorne HY, et al. Ataluren/Ivacaftor combination therapy: two N-of-1 trials in cystic fibrosis patients with nonsense mutations. Pediatr Pulmonol. 2020;55(7):1838–1842. doi: 10.1002/ppul.24764
   PubMed Web of Science ®Google Scholar
• Eloxx pharmaceuticals reports positive topline results from monotherapy arms of Phase 2 clinical trial of ELX-02 in class 1 cystic fibrosis patients [Internet]. Available from: https://investors.eloxxpharma.com/node/11986/pdf.
   Google Scholar
• Eloxx pharmaceuticals reports topline results from Phase 2 combination clinical trial of ELX-02 in class 1 cystic fibrosis (CF) patients [Internet]. Available from: https://www.globenewswire.com/newsrelease/2022/09/14/2516392/0/en/Eloxx-PharmaceuticalsReports-Topline-Results-from-Phase-2-Combination-ClinicalTrial-of-ELX-02-in-Class-1-Cystic-Fibrosis-CF-Patients.html.
   Google Scholar
• Sharma J, Du M, Wong E, et al. A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion. Nat Commun. 2021;12(1):4358. doi: 10.1038/s41467-021-24575-x
   PubMed Web of Science ®Google Scholar
• Ng MY, Li H, Ghelfi MD, et al. Ataluren and aminoglycosides stimulate read-through of nonsense codons by orthogonal mechanisms. Proc Natl Acad Sci U S A. 2021;118(2):e2020599118. doi: 10.1073/pnas.2020599118
   PubMed Web of Science ®Google Scholar
• Kingwell K. FDA OKs first in vitro route to expanded approval. Nat Rev Drug Discov. 2017;16(9):591–592. doi: 10.1038/nrd.2017.140.
   PubMed Web of Science ®Google Scholar
• Durmowicz AG, Lim R, Rogers H, et al. The U.S. food and drug administration’s experience with ivacaftor in cystic fibrosis. establishing efficacy using in vitro data in Lieu of a clinical trial. Ann Am Thorac Soc. 2018;15(1):1–2. doi: 10.1513/AnnalsATS.201708-668PS
   PubMed Web of Science ®Google Scholar
• Clancy JP, Cotton CU, Donaldson SH, et al. CFTR modulator theratyping: current status, gaps and future directions. J Cyst Fibros. 2019;18(1):22–34. doi: 10.1016/j.jcf.2018.05.004
   PubMed Web of Science ®Google Scholar
• Van Goor F, Straley KS, Cao D, et al. Rescue of ΔF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol - Lung Cell Mol Physiol. 2006;290(6):L1117–L1130. doi: 10.1152/ajplung.00169.2005
   PubMed Web of Science ®Google Scholar
• Randell SH, Fulcher ML, O’Neal W, et al. Primary epithelial cell models for cystic fibrosis research. Methods Mol Biol. 2011;742:285–310.
   PubMedGoogle Scholar
• Gentzsch M, Boyles SE, Cheluvaraju C, et al. Pharmacological rescue of conditionally reprogrammed cystic fibrosis bronchial epithelial cells. Am J Respir Cell Mol Biol. 2017;56(5):568–574. doi: 10.1165/rcmb.2016-0276MA
   PubMed Web of Science ®Google Scholar
• Lee RE, Lewis CA, He L, et al. Small-molecule eRf3a degraders rescue CFTR nonsense mutations by promoting premature termination codon readthrough. J Clin Invest. 2022;132(18):e154571. doi: 10.1172/JCI154571
   PubMed Web of Science ®Google Scholar
• Mosler K, Coraux C, Fragaki K, et al. Feasibility of nasal epithelial brushing for the study of airway epithelial functions in CF infants. J Cyst Fibros. 2008;7(1):44–53. doi: 10.1016/j.jcf.2007.04.005
   PubMed Web of Science ®Google Scholar
• Brewington JJ, Filbrandt ET, LaRosa FJ, et al. Brushed nasal epithelial cells are a surrogate for bronchial epithelial CFTR studies. JCI Insight. 3 2018;3(13). doi: 10.1172/jci.insight.99385.
   Web of Science ®Google Scholar
• Baradaran-Heravi A, Balgi AD, Hosseini-Farahabadi S, et al. Effect of small molecule eRF3 degraders on premature termination codon readthrough. Nucleic Acids Res. 2021;49(7):3692–3708. doi: 10.1093/nar/gkab194
   PubMed Web of Science ®Google Scholar
• Nishiguchi G, Keramatnia F, Min J, et al. Identification of potent, selective, and orally bioavailable small-molecule GSPT1/2 degraders from a focused library of cereblon modulators. J Med Chem. 2021;64(11):7296–7311. doi: 10.1021/acs.jmedchem.0c01313
   PubMed Web of Science ®Google Scholar
• Gopalsamy A, Bennett EM, Shi M, et al. Identification of pyrimidine derivatives as Hsmg-1 inhibitors. Bioorg Med Chem Lett [InternetAvailable from]. 2012;22:6636–6641. doi: 10.1016/j.bmcl.2012.08.107
   PubMed Web of Science ®Google Scholar
• Venturini A, Borrelli A, Musante I, et al. Comprehensive analysis of combinatorial pharmacological treatments to correct nonsense mutations in the cftr gene. Int J Mol Sci. 2021;22(21):11972. doi: 10.3390/ijms222111972
   PubMed Web of Science ®Google Scholar
• Spelier S, de Poel E, Ithakisiou GN, et al. High-throughput functional assay in cystic fibrosis patient-derived organoids allows drug repurposing. ERJ Open Res. 2023;9(1):00495–02022. doi: 10.1183/23120541.00495-2022
   PubMedGoogle Scholar
• Mutyam V, Du M, Xue X, et al. Discovery of clinically approved agents that promote suppression of cystic fibrosis transmembrane conductance regulator nonsense mutations. Am J Respir Crit Care Med. 2016;194(9):1092–1103. doi: 10.1164/rccm.201601-0154OC
   PubMed Web of Science ®Google Scholar
• Molinski SV, Ahmadi S, Ip W, et al. O rkambi® and amplifier co-therapy improves function from a rare CFTR mutation in gene-edited cells and patient tissue. EMBO Mol Med. 2017;9(9):1224–1243. doi: 10.15252/emmm.201607137
   PubMed Web of Science ®Google Scholar
• Dukovski D, Villella A, Bastos C, et al. Amplifiers co-translationally enhance CFTR biosynthesis via PCBP1-mediated regulation of CFTR mRNA. J Cyst Fibros. 2020;19(5):733–741. Internet. doi: 10.1016/j.jcf.2020.02.006
   PubMed Web of Science ®Google Scholar
• Giuliano KA, Wachi S, Drew L, et al. Use of a high-throughput phenotypic screening strategy to identify amplifiers, a novel pharmacological class of small molecules that exhibit functional synergy with potentiators and correctors. SLAS Discov. 2018;23(2):111–121. doi: 10.1177/2472555217729790
   PubMed Web of Science ®Google Scholar
• Bengtson C, Silswal N, Baumlin N, et al. The CFTR amplifier nesolicaftor rescues TGF-β1 Inhibition of modulator-Corrected F508del CFTR function. Int J Mol Sci. 2022;23(18):23. doi: 10.3390/ijms231810956
   Web of Science ®Google Scholar
• Smith E, Dukovski D, Shumate J, et al. Identification of compounds that promote readthrough of premature termination codons in the CFTR. SLAS Discov. 2021;26(2):205–215. doi: 10.1177/2472555220962001
   PubMed Web of Science ®Google Scholar
• Crawford DK, Mullenders J, Pott J, et al. Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids. J Cyst Fibros. 2021;20(3):436–442. doi: 10.1016/j.jcf.2021.01.009
   PubMed Web of Science ®Google Scholar
• Keenan MM, Huang L, Jordan NJ, et al. Nonsense-mediated RNA decay pathway inhibition restores expression and function of W1282X CFTR. Am J Respir Cell Mol Biol. 2019;61(3):290–300. doi: 10.1165/rcmb.2018-0316OC
   PubMed Web of Science ®Google Scholar
• Mutyam V, Sharma J, Li Y, et al. Novel correctors and potentiators enhance translational readthrough in CFTR nonsense mutations. Am J Respir Cell Mol Biol. 2021;64(5):604–616. doi: 10.1165/rcmb.2019-0291OC
   PubMed Web of Science ®Google Scholar
• Laselva O, Eckford PD, Bartlett C, et al. Functional rescue of c.3846G>A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of action. J Cyst Fibros. 2020;19(5):717–727. doi: 10.1016/j.jcf.2019.12.001
   PubMed Web of Science ®Google Scholar
• Zhou Z, Duerr J, Johannesson B, et al. The ENaC-overexpressing mouse as a model of cystic fibrosis lung disease. J Cyst Fibros. 2011;10(2):S172–82. doi: 10.1016/S1569-1993(11)60021-0
   PubMed Web of Science ®Google Scholar
• Moore PJ, Tarran R. The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease. Expert Opin Ther Targets. 2018;22(8):687–701. doi: 10.1080/14728222.2018.1501361
   PubMed Web of Science ®Google Scholar
• App EM, King M, Helfesrieder R, et al. Acute and long-term amiloride inhalation in cystic fibrosis lung disease: a rational approach to cystic fibrosis therapy. Am Rev Respir Dis. 1990;141(3):605–612. doi: 10.1164/ajrccm/141.3.605
   PubMed Web of Science ®Google Scholar
• Knowles MR, Church NL, Waltner WE, et al. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med. 1990;322(17):1189–1194. doi: 10.1056/NEJM199004263221704
   PubMed Web of Science ®Google Scholar
• Scheffer GL, Pijnenborg ACLM, Smit EF, et al. Multidrug resistance related molecules in human and murine lung. J Clin Pathol. 2002;55(5):332–339. doi: 10.1136/jcp.55.5.332
   PubMed Web of Science ®Google Scholar
• Danahay H, Gosling M. TMEM16A: an alternative approach to restoring airway Anion secretion in cystic fibrosis? Int J Mol Sci. 2020;21(7):2386. doi: 10.3390/ijms21072386
   PubMed Web of Science ®Google Scholar
• Danahay H, McCarthy C, Gosling M. ePS1.08 a systematic comparison of the profiles of inhaled ENaC blocker candidates on mucociliary clearance: are we under-dosing in clinical studies? J Cyst Fibros. 2019;18:S41. doi: 10.1016/S1569-1993(19)30247-4
   Google Scholar
• Caputo A, Caci E, Ferrera L, et al. TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science. 2008;322(5901):590–594. doi: 10.1126/science.1163518
   PubMed Web of Science ®Google Scholar
• Schroeder BC, Cheng T, Jan YN, et al. Expression cloning of TMEM16A as a calcium-activated chloride channel subunit. Cell. 2008;134(6):1019–1029. doi: 10.1016/j.cell.2008.09.003
   PubMed Web of Science ®Google Scholar
• Yang YD, Cho H, Koo JY, et al. TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature. 2008;455(7217):1210–1215. doi: 10.1038/nature07313
   PubMed Web of Science ®Google Scholar
• Scudieri P, Caci E, Bruno S, et al. Association of TMEM16A chloride channel overexpression with airway goblet cell metaplasia. J Physiol. 2012;590(23):6141–6155. doi: 10.1113/jphysiol.2012.240838
   PubMed Web of Science ®Google Scholar
• Gorrieri G, Scudieri P, Caci E, et al. Goblet cell hyperplasia requires high bicarbonate transport to support mucin release. Sci Rep. 2016;6(1):36016. doi: 10.1038/srep36016
   PubMedGoogle Scholar
• Galietta LJV. TMEM16A (ANO1) as a therapeutic target in cystic fibrosis. Curr Opin Pharmacol. 2022;64:102206. doi: 10.1016/j.coph.2022.102206
   PubMed Web of Science ®Google Scholar
• Pinto MC, Silva IAL, Figueira MF, et al. Pharmacological modulation of ion channels for the treatment of cystic fibrosis. J Exp Pharmacol. 2021;13:693–723. DOI:10.2147/JEP.S255377
   PubMedGoogle Scholar
• Centeio R, Ousingsawat J, Cabrita I, et al. Mucus release and airway constriction by TMEM16A may Worsen pathology in inflammatory lung disease. Int J Mol Sci. 2021;22(15):7852. doi: 10.3390/ijms22157852
   PubMed Web of Science ®Google Scholar
• Kunzelmann K, Ousingsawat J, Cabrita I, et al. TMEM16A in cystic fibrosis: activating or inhibiting? Front Pharmacol. 2019;10:3. DOI:10.3389/fphar.2019.00003
   PubMed Web of Science ®Google Scholar
• Accurso FJ, Moss RB, Wilmott RW, et al. Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. Am J Respir Crit Care Med. 2011;183(5):627–634. doi: 10.1164/rccm.201008-1267OC
   PubMed Web of Science ®Google Scholar
• Ratjen F, Durham T, Navratil T, et al. Long term effects of denufosol tetrasodium in patients with cystic fibrosis. J Cyst Fibros [InternetAvailable from]. 2012;11:539–549. doi: 10.1016/j.jcf.2012.05.003
   PubMed Web of Science ®Google Scholar
• Moss RB. Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis. J Pediatr. 2013;162:676–680. InternetAvailable from. doi: 10.1016/j.jpeds.2012.11.034
   PubMed Web of Science ®Google Scholar
• Namkung W, Yao Z, Finkbeiner WE, et al. Small‐molecule activators of TMEM16A, a calcium‐activated chloride channel, stimulate epithelial chloride secretion and intestinal contraction. Faseb J. 2011;25(11):4048–4062. doi: 10.1096/fj.11-191627
   PubMed Web of Science ®Google Scholar
• Genovese M, Borrelli A, Venturini A, et al. TRPV4 and purinergic receptor signalling pathways are separately linked in airway epithelia to CFTR and TMEM16A chloride channels. J Physiol. 2019;597(24):5859–5878. doi: 10.1113/JP278784
   PubMed Web of Science ®Google Scholar
• Danahay HL, Lilley S, Fox R, et al. TMEM16A potentiation: a novel therapeutic approach for the treatment of cystic fibrosis. Am J Respir Crit Care Med. 2020;201(8):946–954. doi: 10.1164/rccm.201908-1641OC
   PubMed Web of Science ®Google Scholar
• Rehman T, Thornell IM, Pezzulo AA, et al. TNFα and IL-17 alkalinize airway surface liquid through CFTR and pendrin. Am J Physiol - Cell Physiol. 2020;319(2):C331–C344. doi: 10.1152/ajpcell.00112.2020
   PubMed Web of Science ®Google Scholar
• Pedemonte N, Caci E, Sondo E, et al. Thiocyanate transport in resting and IL-4-stimulated human bronchial epithelial cells: role of pendrin and anion channels. J Immunol. 2007;178(8):5144–5153. doi: 10.4049/jimmunol.178.8.5144
   PubMed Web of Science ®Google Scholar
• Adams KM, Abraham V, Spielman D, et al. IL-17A induces Pendrin expression and chloride-bicarbonate exchange in human bronchial epithelial cells. PLoS One. 2014;9(8):e103263. doi: 10.1371/journal.pone.0103263
   PubMed Web of Science ®Google Scholar
• Garnett JP, Hickman E, Burrows R, et al. Novel role for pendrin in orchestrating bicarbonate secretion in cystic fibrosis transmembrane conductance regulator (CFTR)-expressing airway serous cells. J Biol Chem. 2011;286(47):41069–41082. doi: 10.1074/jbc.M111.266734
   PubMed Web of Science ®Google Scholar
• Garnett JP, Turner MJ. Controversies surrounding the role of CFTR in airway bicarbonate secretion. J Physiol. 2013;591(9):2241–2242. doi: 10.1113/jphysiol.2013.251199
   PubMed Web of Science ®Google Scholar
• Zajac M, Dreano E, Edwards A, et al. Airway surface liquid pH regulation in airway epithelium current understandings and gaps in knowledge. Int J Mol Sci. 2021;22(7):22. doi: 10.3390/ijms22073384
   Web of Science ®Google Scholar
• Wang Y, Soyombo AA, Shcheynikov N, et al. Slc26a6 regulates CFTR activity in vivo to determine pancreatic duct HCO3− secretion: relevance to cystic fibrosis. Embo J. 2006;25(21):5049–5057. doi: 10.1038/sj.emboj.7601387
   PubMed Web of Science ®Google Scholar
• Simonin J, Bille E, Crambert G, et al. Airway surface liquid acidification initiates host defense abnormalities in cystic fibrosis. Sci Rep. 2019;9(1):6516. doi: 10.1038/s41598-019-42751-4
   PubMedGoogle Scholar
• Kim D, Huang J, Billet A, et al. Pendrin mediates bicarbonate secretion and enhances cystic fibrosis transmembrane conductance regulator function in airway surface epithelia. Am J Respir Cell Mol Biol. 2019;60(6):705–716. doi: 10.1165/rcmb.2018-0158OC
   PubMed Web of Science ®Google Scholar
• Lohi H, Kujala M, Makela S, et al. Functional characterization of three novel tissue-specific anion exchangers SLC26A7, -A8, and -A9. J Biol Chem. 2002;277(16):14246–14254. doi: 10.1074/jbc.M111802200
   PubMed Web of Science ®Google Scholar
• Avella M, Loriol C, Boulukos K, et al. SLC26A9 stimulates CFTR expression and function in human bronchial cell lines. J Cell Physiol. 2011;226(1):212–223. doi: 10.1002/jcp.22328
   PubMed Web of Science ®Google Scholar
• Bertrand CA, Zhang R, Pilewski JM, et al. SLC26A9 is a constitutively active, CFTR-regulated anion conductance in human bronchial epithelia. J Gen Physiol. 2009;133(4):421–438. doi: 10.1085/jgp.200810097
   PubMed Web of Science ®Google Scholar
• Li H, Salomon JJ, Sheppard DN, et al. Bypassing CFTR dysfunction in cystic fibrosis with alternative pathways for anion transport. Curr Opin Pharmacol [InternetAvailable from]. 2017;34:91–97. doi: 10.1016/j.coph.2017.10.002
   PubMed Web of Science ®Google Scholar
• Anagnostopoulou P, Riederer B, Duerr J, et al. SLC26A9-mediated chloride secretion prevents mucus obstruction in airway inflammation. J Clin Invest. 2012;122(10):3629–3634. doi: 10.1172/JCI60429
   PubMed Web of Science ®Google Scholar
• Strug LJ, Gonska T, He G, et al. Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics. Hum Mol Genet. 2016;25:4590–4600. DOI:10.1093/hmg/ddw290
   PubMed Web of Science ®Google Scholar
• Chen A-P, Chang M-H, Romero MF. Functional analysis of nonsynonymous single nucleotide polymorphisms in human SLC26A9. Hum Mutat. 2012;33(8):1275–1284. doi: 10.1002/humu.22107
   PubMed Web of Science ®Google Scholar
• Pereira SVN, Ribeiro JD, Bertuzzo CS, et al. Interaction among variants in the SLC gene family (SLC6A14, SLC26A9, SLC11A1, and SLC9A3) and CFTR mutations with clinical markers of cystic fibrosis. Pediatr Pulmonol. 2018;53(7):888–900. doi: 10.1002/ppul.24005
   PubMed Web of Science ®Google Scholar
• Corvol H, Mésinèle J, Douksieh IH, et al. SLC26A9 gene is associated with lung function response to ivacaftor in patients with cystic fibrosis. Front Pharmacol. 2018;9:828. DOI:10.3389/fphar.2018.00828
   PubMed Web of Science ®Google Scholar
• Scudieri P, Musante I, Caci E, et al. Increased expression of ATP12A proton pump in cystic fibrosis airways. JCI Insight. 2018;3(20):e123616. doi: 10.1172/jci.insight.123616
   PubMed Web of Science ®Google Scholar
• Coakley RD, Grubb BR, Paradiso AM, et al. Abnormal surface liquid pH regulation by cultured cystic fibrosis bronchial epithelium. Proc Natl Acad Sci U S A. 2003;100(26):16083–16088. doi: 10.1073/pnas.2634339100
   PubMed Web of Science ®Google Scholar
• Shah VS, Ernst S, Tang XX, et al. Relationships among CFTR expression, HCO 3 − secretion, and host defense may inform gene- and cell-based cystic fibrosis therapies. Proc Natl Acad Sci, USA. 2016;113(19):5382–5387. doi: 10.1073/pnas.1604905113
   PubMed Web of Science ®Google Scholar
• Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov. 2021;20:817–838. doi: 10.1038/s41573-021-00283-5
   PubMed Web of Science ®Google Scholar
• Lopes-Pacheco M, Silva PL, Cruz FF, et al. Pathogenesis of multiple organ injury in COVID-19 and potential therapeutic strategies. Front Physiol. 2021;12:593223. DOI:10.3389/fphys.2021.593223
   PubMed Web of Science ®Google Scholar
• Rowe SM, Zuckerman JB, Dorgan D, et al. Inhaled mRNA therapy for treatment of cystic fibrosis: interim results of a randomized, double-blind, placebo-controlled phase 1/2 clinical study. J Cyst Fibros. 2023. doi:10.1016/j.jcf.2023.04.008.
   Google Scholar
• 4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease to be Presented at NACFC 2022 [Internet]. Available from: https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4d-molecular-therapeutics-interim-clinical-data-going-phase-12/.
   Google Scholar
• Sondhi D, Stiles KM, De BP, et al. Genetic modification of the lung directed toward treatment of human disease. Hum Gene Ther. 2017;28(1):3–84. doi: 10.1089/hum.2016.152
   PubMed Web of Science ®Google Scholar
• Alton EWFW, Boyd AC, Davies JC, et al. Genetic medicines for CF: hype versus reality. Pediatr Pulmonol. 2016;51(S44):S5–S17. doi: 10.1002/ppul.23543
   PubMedGoogle Scholar
• Cooney AL, McCray PB, Sinn PL. Cystic fibrosis gene therapy: looking back, looking forward. Genes (Basel). 2018;9(11):538. doi: 10.3390/genes9110538
   PubMed Web of Science ®Google Scholar
• 4D Molecular Therapeutics Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease at NACFC 2022 [Internet]. Available from: https://www.globenewswire.com/news-release/2022/11/03/2547895/0/en/4D-Molecular-Therapeutics-Announces-Interim-Clinical-Data-from-Phase-1-2-Clinical-Trial-of-4D-710-for-Cystic-Fibrosis-Lung-Disease-at-NACFC-2022.html.
   Google Scholar
• Okuda K, Shaffer KM, Ehre C. Mucins and CFTR: their close relationship. Int J Mol Sci. 2022;23(18):10232. doi: 10.3390/ijms231810232
   PubMed Web of Science ®Google Scholar
• Cheng Q, Wei T, Farbiak L, et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing. Nat Nanotech. 2020;15(4):313–320. doi: 10.1038/s41565-020-0669-6
   PubMed Web of Science ®Google Scholar
• Piotrowski-Daspit AS, Barone C, Lin C-Y, et al. In vivo correction of cystic fibrosis mediated by PNA nanoparticles. Sci Adv. 2022;8(40):eabo0522. doi: 10.1126/sciadv.abo0522
   PubMed Web of Science ®Google Scholar
• Montoro DT, Haber AL, Biton M, et al. A revised airway epithelial hierarchy includes CFTR-expressing ionocytes. Nature. 2018;560(7718):319–324. doi: 10.1038/s41586-018-0393-7
   PubMed Web of Science ®Google Scholar
• Plasschaert LW, Žilionis R, Choo-Wing R, et al. A single-cell atlas of the airway epithelium reveals the CFTR-rich pulmonary ionocyte. Nature. 2018;560(7718):377–381. doi: 10.1038/s41586-018-0394-6
   PubMed Web of Science ®Google Scholar
• Okuda K, Dang H, Kobayashi Y, et al. Secretory cells dominate airway CFTR expression and function in human airway superficial epithelia. Am J Respir Crit Care Med. 2021;203(10):1275–1289. doi: 10.1164/rccm.202008-3198OC
   PubMed Web of Science ®Google Scholar
• Carraro G, Langerman J, Sabri S, et al. Transcriptional analysis of cystic fibrosis airways at single-cell resolution reveals altered epithelial cell states and composition. Nat Med. 2021;27(5):806–814. InternetAvailable from. doi: http://dx.doi.org/10.1038/s41591-021-01332-7
   PubMed Web of Science ®Google Scholar
• Goldfarbmuren KC, Jackson ND, Sajuthi SP, et al. Dissecting the cellular specificity of smoking effects and reconstructing lineages in the human airway epithelium. Nat Commun. 2020;11(1):2485. doi: 10.1038/s41467-020-16239-z
   PubMed Web of Science ®Google Scholar
• Boon M, Verleden SE, Bosch B, et al. Morphometric Analysis of Explant Lungs in Cystic Fibrosis. Am J Respir Crit Care Med. 2016;193(5):516–526. doi: 10.1164/rccm.201507-1281OC
   PubMed Web of Science ®Google Scholar
• Anzalone AV, Koblan LW, Liu DR. Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol. 2020;38(7):824–844. doi: 10.1038/s41587-020-0561-9
   PubMed Web of Science ®Google Scholar
• Ensinck M, Mottais A, Detry C, et al. On the corner of models and cure: gene editing in cystic fibrosis. Front Pharmacol. 2021;12:662110. DOI:10.3389/fphar.2021.662110
   PubMed Web of Science ®Google Scholar
• Maule G, Ensinck M, Bulcaen M, et al. Rewriting CFTR to cure cystic fibrosis. Prog Mol Biol Transl Sci. 2021;182:185–224.
   PubMed Web of Science ®Google Scholar
• Urnov FD. Imagine CRISPR cures. Mol Ther. 2021;29(11):3103–3106. doi: 10.1016/j.ymthe.2021.10.019
   PubMed Web of Science ®Google Scholar
• Marquez Loza LI, Cooney AL, Dong Q, et al. Increased CFTR expression and function from an optimized lentiviral vector for cystic fibrosis gene therapy. Mol Ther - Methods Clin Dev. 2021;21:94–106. DOI:10.1016/j.omtm.2021.02.020
   PubMed Web of Science ®Google Scholar
• Alton EWFW, Armstrong DK, Ashby D, et al. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015;3(9):684–691. doi: 10.1016/S2213-2600(15)00245-3
   PubMed Web of Science ®Google Scholar
• Alton EWFW, Beekman JM, Boyd AC, et al. Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis. Thorax. 2017;72(2):137–147. doi: 10.1136/thoraxjnl-2016-208406
   PubMed Web of Science ®Google Scholar
• Vidović D, Carlon MS, da Cunha MF, et al. Raav-CFTRΔR rescues the cystic fibrosis phenotype in human intestinal organoids and cystic fibrosis mice. Am J Respir Crit Care Med. 2016;193(3):288–298. doi: 10.1164/rccm.201505-0914OC
   PubMed Web of Science ®Google Scholar
• Steines B, Dickey DD, Bergen J, et al. CFTR gene transfer with AAV improves early cystic fibrosis pig phenotypes. JCI Insight. 2016;1(14):e88728. doi: 10.1172/jci.insight.88728
   PubMed Web of Science ®Google Scholar
• Cooney AL, Abou Alaiwa MH, Shah VS, et al. Lentiviral-mediated phenotypic correction of cystic fibrosis pigs. JCI Insight. 2016;1(14):e88730. doi: 10.1172/jci.insight.88730
   PubMed Web of Science ®Google Scholar
• Guan S, Munder A, Hedtfeld S, et al. Self-assembled peptide–poloxamine nanoparticles enable in vitro and in vivo genome restoration for cystic fibrosis. Nat Nanotech. 2019;14(3):287–297. doi: 10.1038/s41565-018-0358-x
   PubMed Web of Science ®Google Scholar
• Vaidyanathan S, Baik R, Chen L, et al. Targeted replacement of full-length CFTR in human airway stem cells by CRISPR-Cas9 for pan-mutation correction in the endogenous locus. Mol Ther. 2022;30(1):223–237. doi: 10.1016/j.ymthe.2021.03.023
   PubMed Web of Science ®Google Scholar
• Haque AKMA, Dewerth A, Antony JS, et al. Chemically modified hCFTR mRnas recuperate lung function in a mouse model of cystic fibrosis. Sci Rep. 2018;8(1):16776. doi: 10.1038/s41598-018-34960-0
   PubMedGoogle Scholar
• Kolonko AK, Efing J, González-Espinosa Y, et al. Capsaicin-loaded chitosan nanocapsules for wtCFTR-Mrna delivery to a cystic fibrosis cell line. Biomedicines. 2020;8(9):364. doi: 10.3390/biomedicines8090364
   PubMed Web of Science ®Google Scholar
• Suzuki S, Crane AM, Anirudhan V, et al. Highly efficient gene editing of cystic fibrosis patient-derived airway basal cells results in functional CFTR correction. Mol Ther. 2020;28(7):1684–1695. doi: 10.1016/j.ymthe.2020.04.021
   PubMed Web of Science ®Google Scholar
• Bednarski C, Tomczak K, Vom Hövel B, et al. Targeted Integration of a super-exon into the CFTR locus leads to functional correction of a cystic fibrosis cell line model. PLoS One. 2016;11(8):e0161072. doi: 10.1371/journal.pone.0161072
   PubMed Web of Science ®Google Scholar
• Oren YS, Irony-Tur Sinai M, Golec A, et al. Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation. J Cyst Fibros. 2021;20(5):865–875. doi: 10.1016/j.jcf.2021.06.003
   PubMed Web of Science ®Google Scholar
• Michaels WE, Bridges RJ, Hastings ML. Antisense oligonucleotide-mediated correction of CFTR splicing improves chloride secretion in cystic fibrosis patient-derived bronchial epithelial cells. Nucleic Acids Res. 2020;48:7454–7467.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Sivetz N, Layne J, et al. Exon-skipping antisense oligonucleotides for cystic fibrosis therapy. Proc Natl Acad Sci U S A. 2022;119(3):e2114858118. doi: 10.1073/pnas.2114858118
   PubMed Web of Science ®Google Scholar
• Maule G, Casini A, Montagna C, et al. Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing. Nat Commun. 2019;10(1):3556. doi: 10.1038/s41467-019-11454-9
   PubMedGoogle Scholar
• Sanz DJ, Hollywood JA, Scallan MF, et al. Cas9/gRNA targeted excision of cystic fibrosis-causing deep-intronic splicing mutations restores normal splicing of CFTR mRNA. PLoS One. 2017;12(9):e0184009. doi: 10.1371/journal.pone.0184009
   PubMed Web of Science ®Google Scholar
• Lueck JD, Yoon JS, Perales-Puchalt A, et al. Engineered transfer RNAs for suppression of premature termination codons. Nat Commun. 2019;10(1):822. doi: 10.1038/s41467-019-08329-4
   PubMedGoogle Scholar
• Ko W, Porter JJ, Sipple MT, et al. Efficient suppression of endogenous CFTR nonsense mutations using anticodon-engineered transfer RNAs. Mol Ther Nucleic Acids. 2022;28:685–701.
   PubMedGoogle Scholar
• ReCode therapeutics presents preclinical data using SORT-LNPTM and RNA platforms to rescue CFTR function at the 44th European cystic fibrosis conference (ECFS). Available from: https://recodetx.com/recode-therapeutics-presents-preclinical-data-using-sort-lnptm-and-rna-platforms-to-rescue-cftr-function-at-the-44th-european-cystic-fibrosis-conference-ecfs/.
   Google Scholar
• Vaidyanathan S, Salahudeen AA, Sellers ZM, et al. High-efficiency, selection-free gene repair in airway stem cells from cystic fibrosis patients rescues CFTR function in differentiated epithelia. Cell Stem Cell. 2020;26(2):161–171.e4. doi: 10.1016/j.stem.2019.11.002
   PubMed Web of Science ®Google Scholar
• Santos L, Mention K, Cavusoglu-Doran K, et al. Comparison of Cas9 and Cas12a CRISPR editing methods to correct the W1282X-CFTR mutation. J Cyst Fibros. 2022;21(1):181–187. doi: 10.1016/j.jcf.2021.05.014
   PubMed Web of Science ®Google Scholar
• Geurts MH, de Poel E, Amatngalim GD, et al. CRISPR-Based Adenine editors correct nonsense mutations in a cystic fibrosis organoid biobank. Cell Stem Cell. 2020;26(4):503–510.e7. doi: 10.1016/j.stem.2020.01.019
   PubMed Web of Science ®Google Scholar
• Amistadi S, Maule G, Ciciani M, et al. Functional restoration of a CFTR splicing mutation through RNA delivery of CRISPR adenine base editor. Mol Ther. 2023;31(6):1647–1660. doi: 10.1016/j.ymthe.2023.03.004
   PubMed Web of Science ®Google Scholar
• Krishnamurthy S, Traore S, Cooney AL, et al. Functional correction of CFTR mutations in human airway epithelial cells using adenine base editors. Nucleic Acids Res. 2021;49(18):10558–10572. doi: 10.1093/nar/gkab788
   PubMed Web of Science ®Google Scholar
• Geurts MH, de Poel E, Pleguezuelos-Manzano C, et al. Evaluating CRISPR-based prime editing for cancer modeling and CFTR repair in organoids. Life Sci Alliance. 2021;4(10):e202000940. doi: 10.26508/lsa.202000940
   PubMed Web of Science ®Google Scholar
• Schene IF, Joore IP, Baijens JHL, et al. Mutation-specific reporter for optimization and enrichment of prime editing. Nat Commun. 2022;13(1):1028. doi: 10.1038/s41467-022-28656-3
   PubMed Web of Science ®Google Scholar
• Doman JL, Sousa AA, Randolph PB, et al. Designing and executing prime editing experiments in mammalian cells. Nat Protoc. 2022;17(11):2431–2468. doi: 10.1038/s41596-022-00724-4
   PubMed Web of Science ®Google Scholar
• Harrison PT. CFTR RNA- and DNA-based therapies. Curr Opin Pharmacol. 2022;65:102247. doi: 10.1016/j.coph.2022.102247
   PubMed Web of Science ®Google Scholar
• Hodges CA, Conlon RA. Delivering on the promise of gene editing for cystic fibrosisx. Genes Dis. 2019;6(2):97–108. doi: 10.1016/j.gendis.2018.11.005
   PubMed Web of Science ®Google Scholar
• Costa E, Girotti S, Pauro F, et al. The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis. Orphanet J Rare Dis. 2022;17(1):188. doi: 10.1186/s13023-022-02350-5
   PubMed Web of Science ®Google Scholar
• Cystic fibrosis foundation patient registry - 2021 annual data Report [Internet]. Available from: https://www.cff.org/media/9741/download.
   Google Scholar
• Zampoli M, Morrow BM, Paul G. Real-world disparities and ethical considerations with access to CFTR modulator drugs: mind the gap! Front Pharmacol. 2023;14:1163391.
   PubMed Web of Science ®Google Scholar